Sumitomo Pharma Co Ltd 2021 Integrated Report
The report presents Sumitomo Dainippon Pharma's Integrated Report 2021, detailing its CSR-based management, materiality targets, and digital transformation initiatives under the Mid-term Business Plan 2022. The company established new KPIs to manage progress across material issues and revised its Basic Environmental Policies, setting targets to cut Scope 1 and 2 emissions by 35% by fiscal 2030 and reach net-zero by fiscal 2050. Financial results for fiscal 2020 show revenue of 515.95 billion yen.
Company: Sumitomo Pharma Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2021
Type: Integrated Report
Pages: 178
Back to company
Sumitomo Pharma Co Ltd
Integrated Report
The report presents Sumitomo Dainippon Pharma's Integrated Report 2021, detailing its CSR-based management, materiality targets, and digital transformation initiatives under the Mid-term Business Plan 2022. The company established new KPIs to manage progress across material issues and revised its Basic Environmental Policies, setting targets to cut Scope 1 and 2 emissions by 35% by fiscal 2030 and reach net-zero by fiscal 2050. Financial results for fiscal 2020 show revenue of 515.95 billion yen.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees